SMS Pharmaceuticals' Q3 FY 2025-26 Quarterly Results

Result Summary

• SMS Pharmaceuticals Ltd reported a 12.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 22.1%.
• Its expenses for the quarter were down by 12.8% QoQ and up 19.6% YoY.
• The net profit decreased 7.3% QoQ and increased 28.7% YoY.
• The earnings per share (EPS) of SMS Pharmaceuticals Ltd stood at 2.59 during Q3 FY 2025-26.

Financial Statments for Q3 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

SMS Pharmaceuticals Ltd is a company that operates in the pharmaceutical industry, focusing primarily on the manufacture and distribution of active pharmaceutical ingredients (APIs). The company is known for producing a wide range of APIs that are used in various therapeutic segments. SMS Pharmaceuticals serves both domestic and international markets, leveraging its manufacturing facilities and research capabilities. As of now, no specific recent major developments have been highlighted for SMS Pharmaceuticals Ltd, and additional detailed information on recent strategic initiatives or projects is not available within the scope of the current data.

Revenue

In Q3FY26, SMS Pharmaceuticals Ltd reported a total income of ₹214.20 crores. This represents a decrease of 12.2% compared to the previous quarter, Q2FY26, where the total income was ₹243.86 crores. However, when compared to the same quarter in the previous year, Q3FY25, there is a notable increase of 22.1% from ₹175.48 crores. These figures show the company's revenue fluctuations on a quarterly basis while maintaining a positive growth trajectory year-over-year. The revenue data highlights the company's ability to generate increased income compared to the previous year, despite a quarter-over-quarter decline.

Profitability

The profitability metrics for SMS Pharmaceuticals Ltd in Q3FY26 indicate a profit before tax of ₹31.16 crores, which is an 8.5% decrease from ₹34.04 crores in Q2FY26. Year-over-year, there is a significant increase of 38.9% from ₹22.44 crores in Q3FY25. After accounting for taxes, the profit after tax stands at ₹23.47 crores, down 7.3% from the previous quarter's ₹25.31 crores, but up 28.7% from the ₹18.24 crores reported in Q3FY25. The earnings per share for Q3FY26 is ₹2.59, reflecting an 8.8% decrease from ₹2.84 in Q2FY26, yet a 20.5% increase from ₹2.15 in the same period last year. These profitability metrics outline the company's financial performance, showing a robust year-over-year growth despite a quarter-over-quarter decline.

Operating Metrics

The total expenses for SMS Pharmaceuticals Ltd in Q3FY26 were ₹183.04 crores, which is a 12.8% decrease from ₹209.82 crores in Q2FY26. Compared to the same quarter last year, Q3FY25, this represents a 19.6% increase from ₹153.04 crores. The tax expense for this quarter was ₹7.97 crores, down 10.5% from ₹8.91 crores in Q2FY26, but up 48.7% from ₹5.36 crores in Q3FY25. These operating metrics provide insight into the company's cost structure and tax obligations, reflecting both the cost management strategies and the impact of tax charges on the company's operations. The data shows a decrease in expenses from the previous quarter, with a notable increase compared to the same period last year.